
Substance Use Disorders
Assessment and Treatment
By:Â Charles E. Dodgen, W. Michael Shea
Hardcover | 31 March 2000
At a Glance
174 Pages
24.13 x 15.88 x 1.91
Hardcover
$238.75
or 4 interest-free payments of $59.69 with
 orÂShips in 15 to 25 business days
- A synthesis of the current research and clinical literature
- Includes strengths and weaknesses of commonly used psychometric assessment measures
- Presentation and review of a complete Psychosocial/Substance Use Assessment form
- Discussion of treatment settings and criteria for placement decisions
- Discussion of treatment alternatives and effectiveness of major pharmacological and psychotherapeutic approaches
- Discussion of factors leading to Relapse, and components of Relapse Prevention programs
Industry Reviews
Prepublication Praise "An excellent resource that provides up-to-date information on alcohol and other psychoactive substance use disorders. It illuminates the facts and substantiates them with a myriad of references. This text is useful not only for clinicians working in the field of addictions but for all therapists who will encounter individuals with such a problem. Should be considered essential reading for various additional audiences such as students in graduate or nursing schools. It is well organized and very comprehensive." --RAYMOND F. HANBURY, JR., Ph.D., C.A.S.; Past President, Division 50 (Addictions), American Psychological Association; International Advisory Board, American Academy of Health Care Providers in the Addictive Disorders; President, New Jersey Psychological Association
| Preface | p. xv |
| Acknowledgments | p. xvii |
| Clinical Pharmacology and Clinical Epidemiology of Psychoactive Substances | |
| Definitions and General Concepts of Pharmacology | p. 1 |
| Pharmacology of Individual Drugs | p. 6 |
| Central Nervous System Stimulants | p. 6 |
| Cocaine | p. 7 |
| Amphetamines | p. 9 |
| Caffeine | p. 10 |
| Nicotine | p. 11 |
| Central Nervous System Depressants | p. 12 |
| Alcohol | p. 12 |
| Barbiturates | p. 12 |
| Benzodiazepines | p. 12 |
| Cannabinoids | p. 15 |
| Opioids | p. 17 |
| Heroin | p. 18 |
| Codeine | p. 18 |
| Methadone | p. 18 |
| Hallucinogens | p. 18 |
| Mescaline | p. 18 |
| LSD | p. 19 |
| Psilocybin and Psilocin | p. 20 |
| PCP | p. 20 |
| Solvent and Aerosol Inhalants | p. 21 |
| Steroids | p. 21 |
| Clinical Epidemiology of Psychoactive Substances | p. 22 |
| General Trends | p. 23 |
| Trends of Specific Substance Use | p. 24 |
| Alcohol | p. 24 |
| Other CNS Depressants | p. 24 |
| CNS Stimulants | p. 25 |
| Caffeine | p. 25 |
| Nicotine | p. 25 |
| Marijuana | p. 25 |
| Opioids | p. 26 |
| Hallucinogens | p. 26 |
| Inhalants | p. 26 |
| Steroids | p. 26 |
| References | p. 27 |
| Etiology of Psychoactive Substance Use Disorders | |
| Overview | p. 29 |
| Theories of Etiology | p. 30 |
| Genetic Research | p. 30 |
| Psychological Theories | p. 32 |
| Psychodynamic Theories | p. 32 |
| Behavioral/Cognitive-Behavioral Theories | p. 33 |
| Family Models | p. 34 |
| References | p. 34 |
| Initiation, Progression, and Maintenance of Psychoactive Substance Use Disorders | |
| Stage Models of Adolescent Substance Use | p. 37 |
| Risk Factors | p. 39 |
| Risk Factors for Use versus Abuse | p. 40 |
| Adult Model of Substance Use | p. 41 |
| References | p. 41 |
| Course/Natural History of Psychoactive Substance Use Disorders | |
| The Disease Model | p. 43 |
| Classic Model of Progression of Alcoholism | p. 45 |
| Longitudinal Study of Alcohol Abuse | p. 45 |
| Models of Progression of Substance Use | p. 46 |
| Stage Model of Progression | p. 46 |
| Spontaneous Remission of Substance Abuse | p. 46 |
| Stages of Change Model | p. 46 |
| References | p. 48 |
| Prevention, Early Intervention, and Harm Reduction | |
| General Perspective | p. 51 |
| Types of Prevention | p. 52 |
| Targets of Prevention Efforts | p. 52 |
| Types of Interventions | p. 52 |
| Supply Reduction/Legal Interventions | p. 53 |
| Risk and Protective Factors | p. 54 |
| Risk Factors | p. 54 |
| Broad Social and Cultural Factors Associated with Elevated Risk of Substance Abuse | p. 54 |
| Individual and Interpersonal Environmental Factors Associated with Elevated Risk of Substance Abuse | p. 54 |
| Protective Factors Mitigating Risk of Substance Abuse | p. 55 |
| Skills Training | p. 55 |
| Community-Based Prevention | p. 56 |
| School-Based Programs | p. 57 |
| Parenting/Family Interventions | p. 58 |
| Related Risks/Harm Reduction | p. 59 |
| HIV and Substance Abuse | p. 59 |
| Pregnant Adolescents/Adolescent Mothers | p. 59 |
| Reducing Alcohol Consumption | p. 60 |
| References | p. 60 |
| Screening and Assessment of Psychoactive Substance Use | |
| Overview of the Assessment Process | p. 63 |
| Stage Models of Assessment | p. 63 |
| Illustrative Stage Models of Assessment of Psychoactive Substance Use Disorders | p. 64 |
| Validity of Self-Report Data | p. 64 |
| Factors Associated with Accurate Self-Report of Psychoactive Substance Use | p. 65 |
| Psychometric Properties of Assessment Instruments | p. 65 |
| Alcohol Screening Instruments | p. 67 |
| Michigan Alcohol Screening Test (MAST) | p. 67 |
| CAGE Questionnaire | p. 67 |
| TWEAK | p. 68 |
| Alcohol Use Disorders Identification Test (AUDIT) | p. 68 |
| MacAndrew Alcoholism Scale (MAC) | p. 69 |
| Adolescent-Specific Scales | p. 69 |
| Adolescent Alcohol Involvement Scale (AAIS) | p. 69 |
| MacAndrew Alcoholism Scale for Adolescents (MAC-A) | p. 70 |
| Rutgers Alcohol Problem Index (RAPI) | p. 70 |
| Drug Screening Instruments | p. 70 |
| Drug Abuse Screening Test (DAST) | p. 70 |
| Drug Use Screening Inventory (DUSI) | p. 71 |
| Biological Screening Measures | p. 71 |
| Alcohol-Specific Biological Screening Measures | p. 71 |
| Measurement of Recent Use | p. 71 |
| Measurement of Long-Term Alcohol Abuse | p. 72 |
| Laboratory Assessment of Drugs Other Than Alcohol | p. 73 |
| Methods of Measurement of Recent Use | p. 73 |
| Assessment of Chronic Drug Abuse | p. 74 |
| Diagnostic Instruments | p. 75 |
| The Alcohol Use Disorders and Associated Disabilities Interview Schedule (AUDADIS) | p. 75 |
| Composite International Diagnostic Interview: Authorized Core Version 1.0 (CIDI-Core) | p. 76 |
| Structured Clinical Interview for DSM III-R (SCID) | p. 76 |
| Addiction Severity Index (ASI) | p. 76 |
| Fagerstrom Tolerance Questionnaire (FTQ) | p. 76 |
| Clinical Institute Withdrawal Assessment-Revised (CIWA-AR) | p. 77 |
| Knowledge of Symptoms of Withdrawal and Intoxication | p. 77 |
| Measures of Consumption of Alcohol and Other Substances | p. 78 |
| Lifetime Drinking History (LDH) | p. 78 |
| Quantity-Frequency Methods (QF) | p. 78 |
| Timeline Follow Back (TLFB) | p. 79 |
| Self-Monitoring | p. 79 |
| Knowledge of High-Risk Groups | p. 80 |
| Knowledge of Diagnostic Criteria | p. 81 |
| Areas to Assess for Treatment Planning Purposes | p. 82 |
| Neuropsychological Screening | p. 82 |
| Expectancy Measures | p. 83 |
| Assessment of Motivation for Change | p. 83 |
| Assessment of High-Risk Situations | p. 84 |
| Assessment of Family Functioning | p. 84 |
| Awareness of Common Family Dynamics | p. 84 |
| Illustrative Example and Discussion of a Complete Psychosocial/Substance Use Assessment Form | p. 86 |
| Presentation of the Assessment Form | p. 87 |
| Examples of Specific Questions to Ask and Rationales for Inclusion of Items on the Assessment Form | p. 90 |
| References | p. 98 |
| Diagnosis and Comorbidity | |
| Definition and Prevalence | p. 103 |
| Percentage of Alcohol Abusers Presenting with Comorbid Psychiatric Disorders | p. 104 |
| Percentage of Drug Abusers Presenting with Comorbid Psychiatric Disorders | p. 104 |
| Percentage of Psychiatric Cases Presenting with Substance Abuse or Dependence | p. 104 |
| Diagnostic Issues of the Dually Impaired | p. 104 |
| Complicating Factors | p. 104 |
| Improvement of Diagnostic Validity | p. 106 |
| Illustrative Clinical Cases | p. 107 |
| Treatment of the Dually Diagnosed | p. 109 |
| Traditional Approaches | p. 109 |
| Parallel Treatment Systems | p. 110 |
| Integrated Treatment Systems | p. 110 |
| References | p. 111 |
| Treatment I: Models and Approaches | |
| Treatment Settings and Services | p. 113 |
| Placement Criteria | p. 114 |
| Major Theoretical Treatment Approaches | p. 115 |
| Current Psychoanalytic/Psychodynamic Approaches | p. 116 |
| Neurotic Conflict | p. 116 |
| Ego- and Self-Deficits | p. 116 |
| Deficits in Affective Functioning and Object Relations | p. 117 |
| Psychosomatic Disorders | p. 117 |
| Elements Common to Psychoanalytic Theories of Substance Abuse | p. 117 |
| Strengths and Weaknesses of Psychoanalytic Theories of Substance Abuse | p. 117 |
| Family Therapies | p. 117 |
| Family Disease Model | p. 118 |
| Behavioral Model | p. 118 |
| Family Systems Model | p. 118 |
| Strengths and Weaknesses of Family Theories of Substance Abuse | p. 118 |
| Behavioral/Cognitive Behavioral Approaches | p. 119 |
| Classical Conditioning | p. 119 |
| Operant Conditioning | p. 119 |
| Social Learning Theory | p. 119 |
| Strengths and Weaknesses of Behavioral Approaches to the Treatment of Substance Abuse | p. 119 |
| Client-Centered/Motivational Interviewing | p. 120 |
| Biopsychosocial Model | p. 120 |
| 12-Step Programs | p. 121 |
| Therapeutic Community | p. 121 |
| Additional Psychological Therapies | p. 121 |
| Social Skills Training | p. 122 |
| Contingency Management | p. 122 |
| Aversion Therapies | p. 122 |
| Community Reinforcement Approach (CRA) | p. 122 |
| Relapse Prevention | p. 122 |
| Common Elements of Relapse Prevention Programs | p. 124 |
| Cue Exposure | p. 125 |
| Behavioral Self-Control | p. 125 |
| Stress Management | p. 125 |
| Network Therapy | p. 125 |
| Role of Pharmacotherapy | p. 126 |
| Cocaine | p. 126 |
| Alcohol | p. 127 |
| Opioids | p. 127 |
| Nicotine | p. 128 |
| Treatment Effectiveness/Outcome Studies | p. 130 |
| Therapist Factors | p. 130 |
| Patient Factors | p. 131 |
| Program Services | p. 131 |
| Duration of Treatment | p. 132 |
| Theoretical Orientation | p. 132 |
| Alternative Treatments | p. 133 |
| Acupuncture | p. 133 |
| Transcendental Meditation (TM) | p. 134 |
| Concluding Remarks on Acupuncture and TM | p. 134 |
| References | p. 134 |
| Treatment II: Planning, Implementing, and Managing Treatment and the Course of Recovery | |
| Phases of Recovery | p. 139 |
| Relapse Parameters | p. 140 |
| Treatment Goals | p. 140 |
| Traditional Abstinence Goals | p. 140 |
| Controlled Use of Alcohol | p. 141 |
| Detoxification | p. 141 |
| Engagement of Patients in Treatment | p. 142 |
| Client-Treatment Matching | p. 142 |
| Project Match | p. 143 |
| Treatment of Family Members of Substance Abusers | p. 143 |
| Linkage of Services | p. 144 |
| Treatment of Criminal Offenders | p. 144 |
| Driving-Related Offenders | p. 144 |
| Treatment of the Incarcerated | p. 145 |
| Self-Help Groups | p. 145 |
| Alcoholics Anonymous (AA) and Narcotics Anonymous (NA) | p. 145 |
| AL-ANON and ALATEEN/NAR-ANON and NARATEEN | p. 146 |
| Women for Sobriety | p. 146 |
| Rational Recovery | p. 146 |
| References | p. 146 |
| Issues in Specific Populations | |
| Impaired Physicians | p. 149 |
| Definition and Risk Factors | p. 149 |
| Treatment of Physicians | p. 150 |
| Ethnic Minorities | p. 150 |
| Prevalence and Etiological Factors | p. 150 |
| Cultural Influences on Substance Abuse | p. 151 |
| Treatment of Ethnic Minorities | p. 151 |
| Barriers to Treatment for Ethnic Minorities | p. 151 |
| Women | p. 152 |
| Prevalence of Substance Abuse | p. 152 |
| Barriers to Treatment for Women | p. 152 |
| Treatment Needs of Women | p. 153 |
| HIV/AIDS | p. 153 |
| Prevention with Adolescents | p. 153 |
| Barriers to Treatment for Adolescents | p. 153 |
| Barriers to Treatment and Treatment Needs of Those with HIV/AIDS | p. 153 |
| The Elderly Population | p. 154 |
| Diagnostic Issues | p. 154 |
| Treatment of the Elderly Population | p. 154 |
| The Homeless Population | p. 155 |
| Prevalence of Substance Abuse | p. 155 |
| Underutilization of Services | p. 155 |
| References | p. 155 |
| Legal and Ethical Issues | |
| Confidentiality | p. 157 |
| Rationale for Confidentiality | p. 157 |
| Federal Guidelines for Valid Consent to Disclose Information | p. 158 |
| Disclosure without Patient Consent | p. 159 |
| Confidentiality and HIV Status | p. 159 |
| Confidentiality and Illegal Behavior | p. 160 |
| Confidentiality and Minors | p. 160 |
| Responsibility to Diagnose and Treat Substance Use Disorders | p. 160 |
| Coerced Treatment | p. 161 |
| Driving While Intoxicated (DWI) Programs | p. 161 |
| Referral for Treatment by Social Service Agencies | p. 161 |
| Treatment of Pregnant Mothers | p. 161 |
| Americans with Disabilities Act (ADA) | p. 162 |
| Description of the ADA | p. 162 |
| Application of the ADA to Substance Abusers | p. 163 |
| References | p. 164 |
| Epilogue | p. 165 |
| Index | p. 167 |
| Table of Contents provided by Syndetics. All Rights Reserved. |
ISBN: 9780122191602
ISBN-10: 0122191609
Series: Practical Resources for the Mental Health Professional
Published: 31st March 2000
Format: Hardcover
Language: English
Number of Pages: 174
Audience: Professional and Scholarly
Publisher: ACADEMIC PR INC
Country of Publication: US
Dimensions (cm): 24.13 x 15.88 x 1.91
Weight (kg): 0.42
Shipping
| Standard Shipping | Express Shipping | |
|---|---|---|
| Metro postcodes: | $9.99 | $14.95 |
| Regional postcodes: | $9.99 | $14.95 |
| Rural postcodes: | $9.99 | $14.95 |
Orders over $79.00 qualify for free shipping.
How to return your order
At Booktopia, we offer hassle-free returns in accordance with our returns policy. If you wish to return an item, please get in touch with Booktopia Customer Care.
Additional postage charges may be applicable.
Defective items
If there is a problem with any of the items received for your order then the Booktopia Customer Care team is ready to assist you.
For more info please visit our Help Centre.
You Can Find This Book In

Polyvagal Flip Chart
Understanding the Science of Safety (Norton Series on Interpersonal Neurobiology)
Paperback
RRP $57.95
$38.75
OFF

The Book You Wish Your Parents Had Read (and Your Children Will Be Glad That You Did)
THE #1 SUNDAY TIMES BESTSELLER
Paperback
RRP $26.99
$22.99
OFF

Wild Creature Mind
The Neuroscience Breakthrough That Helps You Transform Anxiety and Live a Fiercely Loving Life
Paperback
RRP $36.99
$29.75
OFF

The Mindful Self-Compassion Workbook
A Proven Way to Accept Yourself, Build Inner Strength, and Thrive
Paperback
RRP $59.99
$41.75
OFF
This product is categorised by
- Non-FictionMedicineOther Branches of MedicineTherapy & TherapeuticsAddiction & Therapy
- Non-FictionMedicineOther Branches of MedicineClinical Psychology
- Non-FictionMedicineOther Branches of MedicinePharmacologyPsychopharmacology
- Non-FictionMedicineClinical & Internal MedicineNeurology & Clinical Neurophysiology




















